Clinical trials: Disease-Free Survival
Non Small Cell Lung Cancer, Small-cell Lung Cancer
DIAGNOSIS, TREATMENT AND OUTCOME OF LUNG CANCER PATIENTS
Observational, prospective clinical research, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with NSCLC or SCLC in Turkey
- Trial name
- REGISTURK-LUNG (NCT05254119)
- Where
- 39 sites in Turkey (Türkiye)
- Volunteers
- 6,000 people
- Sponsor
- Mahmut Gumus
Waldenstrom's Disease, Prognostic Index
Prognostic Analyses on a Validation Series of Patients With Waldenström's Disease
Waldenström's macroglobulinemia (WM) is defined by the association of bone marrow lymphoplasmocytic infiltration and monoclonal immunoglobulin M (IgM).
- Trial name
- SérieProWM (NCT05911802)
- Where
- 15 sites in France
- Volunteers
- 500 people
- Sponsor
- French Innovative Leukemia Organisation
Phenotypic Age Acceleration, Biological Aging Marker
Phenotypic Age Acceleration (PhenoAgeAccel) for Joint Prediction of Disease Risk, Mortality Risk, Life Expectancy, and Disease-Free Healthspan in Major Chronic Diseases
The goal of this observational study is to learn about the ability of Phenotypic Age Acceleration (PhenoAgeAccel) to predict four key health outcomes in Chinese people with or at risk of major chronic diseases: the risk of…
- Conditions
- Phenotypic Age Acceleration, Biological Aging Marker, Mortality Risk Prediction, Disease Risk Prediction
- Trial name
- NCT07595094
- Testing
- No Intervention (Observational Study)
- Where
- China
- Volunteers
- 2,000,000 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital of Nanchang University
Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response
This phase II/III trial compares the effect of usual treatment approach alone (FOLFOX or CAPOX after chemoradiation) with using FOLFIRINOX after chemoradiation in patients with stage II-III rectal cancer.
- Conditions
- Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Locally Advanced Rectal Adenocarcinoma
- Trial name
- JANUS (NCT05610163)
- Testing
- Capecitabine, 5-fluorouracil, Leucovorin calcium
- Where
- 685 sites in United States, Puerto Rico
- Volunteers
- 760 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pancreatic Ductal Adenocarcinoma
Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature
This is a multicentre open labelled phase III adjuvant trial of disease-free survival in patients with resected pancreatic ductal adenocarcinoma randomized to allocation of oxaliplatin- or gemcitabine-based chemotherapy by…
- Trial name
- NCT05314998
- Testing
- Oxaliplatin, Irinotecan, Folinic acid
- Where
- 33 sites in Germany, Sweden
- Volunteers
- 394 people
- Sponsor
- John Neoptolemos
Breast Cancer, Sentinel Lymph Node
Prospective Feasibility Study Applying the ACOSOG Z0011 Criteria to Chinese Patients
In patients undergoing breast-conserving surgery and having positive sentinel lymph nodes (SLNs), the ACOSOG Z0011 trial showed equivalent overall survival(OS) and disease-free survival(DFS) outcomes for patients receiving SLN…
- Conditions
- Breast Cancer, Sentinel Lymph Node, Local Recurrence of Malignant Tumor of Breast
- Trial name
- NCT03606616
- Testing
- no further ALND arm
- Where
- China
- Volunteers
- 142 people
- Sponsor
- Peking University People's Hospital
Colorectal Neoplasms
Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer
The purpose of this study is to evaluate the safety and efficacy of Abraxane (nab-paclitaxel) in subjects with previously treated metastatic colorectal cancer.
- Trial name
- NCT02103062
- Testing
- ABI-007
- Where
- 6 sites in France
- Volunteers
- 41 people
- Sponsor
- Celgene
Leukemia
Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors
The study proposes the use of Fludarabine, Busulfan, Anti Thymocyte Globulin Rabbit (ATG) and Total Body Irradiation as a preparative regimen before hematopoietic stem cell transplant from unrelated donor peripheral blood stem…
- Trial name
- NCT00679536
- Testing
- Busulfan, Fludarabine, Thymoglobulin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Breast Cancer
Radiotherapy After Primary Chemotherapy for Breastcancer
The primary aim of the study is to evaluate the 5 yr locoregional recurrence rate (LRR) in cT1-2cN0-1(cytology/histology and/or positive SN, excluding patients with > 3 pathologic axillary nodes on imaging) breast cancer…
- Trial name
- RAPCHEM (NCT01279304)
- Testing
- radiation - no radiation see intervention description, radiation: see intervention description
- Where
- 6 sites in Netherlands
- Volunteers
- 851 people
- Sponsor
- Maastricht Radiation Oncology
Liver Cancer (Primary and Metastatic), Lung Cancer (Diagnosis)
Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance
This study collects data from patients undergoing minimally invasive, image-guided cancer treatments at participating hospitals in the Netherlands and France.
- Conditions
- Liver Cancer (Primary and Metastatic), Lung Cancer (Diagnosis), Bone Cancer Metastatic, Bone Cancer Tumor
- Trial name
- PreciseOnco (NCT07636148)
- Where
- 3 sites in France, Netherlands
- Volunteers
- 2,000 people
- Sponsor
- Mark C Burgmans, MD PhD
Cryptococcal Antigenemia, HIV-1-infection
Optimizing Care for Cryptococcal Antigenemia: Evaluation of Short Course Fluconazole and ART Timing Among CrAg+ Persons With Low Titers
This randomized clinical trial will evaluate the optimal duration of fluconazole therapy and timing of antiretroviral therapy initiation among HIV-infected persons with asymptomatic cryptococcal antigenemia and low cryptococcal…
- Conditions
- Cryptococcal Antigenemia, HIV-1-infection, Cryptococcal Infection, Cryptococcal Meningitis
- Trial name
- NCT07743593
- Testing
- Immediate ART Initiation, Delayed ART Initiation, 10-Week Fluconazole
- Where
- Uganda
- Volunteers
- 505 people
- Sponsor
- University of Minnesota
Esophageal Adenocarcinoma, Esophageal Cancer
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
An open label phase II study to determine the safety and preliminary efficacy of the combination of 1-year of adjuvant trastuzumab deruxtecan and nivolumab for patients with HER2 overexpressing esophagogastric adenocarcinoma who…
- Conditions
- Esophageal Adenocarcinoma, Esophageal Cancer, HER-2 Protein Overexpression, Gastroesophageal-junction Cancer
- Trial name
- NCT05480384
- Testing
- Nivolumab, Trastuzumab deruxtecan
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Brown University
Stage III Gastric Cancer
Immunonutritional Supplement After Total Gastrectomy in Patients With Stage III Gastric Cancer
Gastric cancer patients with stage III will be randomized to immune nutrition support or control group at discharge after total gastrectomy.
- Trial name
- CRUCIAL (NCT05253716)
- Testing
- ONS
- Where
- China
- Volunteers
- 696 people
- Sponsor
- Jinling Hospital, China
Glioblastoma Multiforme
Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan
The overall purpose of the study is to investigate the efficacy and safety of ALECSAT in patients with relapse of GlioBlastoma Multiforme (GBM) after first line treatments (followed by reoperation if possible).
- Trial name
- NCT02060955
- Testing
- ALECSAT, Bevacizumab/Irinotecan
- Where
- 4 sites in Denmark
- Volunteers
- 25 people
- Sponsor
- CytoVac A/S
Non-small Cell Lung Cancer
IMMUNO-LUNG : Identification of Biomarkers and Therapeutic Targets for Pulmonary Immunotherapy
Immunotherapy has helped improve the prognosis of metastatic lung cancer. However, only about 40% of patients respond to conventional immunotherapy with anti-PD(L)-1 agents.
- Trial name
- IMMUNOLUNG (NCT07608835)
- Testing
- prospective collection of blood and tumor samples
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Institut Paoli-Calmettes
Non-Small Cell Lung Cancer (NSCLC)
Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC
According to literature reports, about 16.3%-19% of newly diagnosed NSCLC patients are associated with brain metastasis, and 30%-50% of NSCLC patients will develop brain metastasis during the whole course of the disease.
- Trial name
- NCT04905550
- Testing
- Almonertinib, Stereotactic Radiotherapy(SRT) or Stereotactic Radiosurgery(SRS) or Whole-Brain Radiotherapy(WBRT)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Chongqing University Cancer Hospital
Triple Negative Breast Cancer, Metastatic Triple-negative Breast Cancer
HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry.
The goal of this clinical trial is to learn if Gemcitabine, a chemotherapy drug that is usually used to treat breast cancer after other treatments have failed, is better at treating triple negative breast cancer in women of…
- Trial name
- NCT07528768
- Testing
- Gemcitabine (1000 mg/m^2), Paclitaxel 80 mg/m2 weekly
- Where
- 3 sites in Barbados, Ghana and 1 more
- Volunteers
- 750 people
- Sponsor
- The University of The West Indies
Gastric Adenocarcinoma, Esophagogastric Junction
Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology
Background: Gastric cancer is a common and serious cancer. Standard treatment is chemotherapy drugs. Researchers want to see if a new treatment helps.
- Conditions
- Gastric Adenocarcinoma, Esophagogastric Junction, Gastric Cancer
- Trial name
- NCT03092518
- Testing
- Surgery, Cisplatin, Mitomycin C
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Relationship of pAKT to Survival in Patients With Node-Positive Breast Cancer
This study will examine the relationship of a protein called pAKT to survival of breast cancer patients with one or more positive axillary lymph nodes.
- Trial name
- NCT00965276
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer, Prostate Adenocarcinoma
High-Risk prostatE Cancer radiatiOn Versus surgERy
Prospective cohort study comparing robot-assisted radical prostatectomy and external beam radiotherapy +/- androgen deprivation therapy for high-risk non-metastatic prostate cancer in terms of health-related quality of life…
- Trial name
- RECOVER (NCT05931419)
- Where
- 28 sites in Netherlands
- Volunteers
- 837 people
- Sponsor
- Comprehensive Cancer Centre The Netherlands